The microglial ATP‐gated ion channel P2X7 as a CNS drug target

Based on promising preclinical evidence, microglial P2X7 has increasingly being recognized as a target for therapeutic intervention in neurological and psychiatric diseases. However, despite this knowledge no P2X7‐related drug has yet entered clinical trials with respect to CNS diseases. We here discuss the current literature on P2X7 being a drug target and identify unsolved issues and still open questions that have hampered the development of P2X7 dependent therapeutic approaches for CNS diseases. It is concluded here that the lack of brain penetrating P2X7 antagonists is a major obstacle in the field and that central P2X7 is a yet untested clinical drug target. In the CNS, microglial P2X7 activation causes neuroinflammation, which in turn plays a role in various CNS disorders. This has resulted in a surge of brain penetrant P2X7 antagonists. P2X7 is a viable, clinically untested CNS drug target. GLIA 2016;64:1772–1787

[1]  Fang,et al.  Stereodivergent Synthesis of 2,3-Disubstituted 1,4-Dicarbonyls , 2018, Synfacts.

[2]  K. Jacobson,et al.  Medicinal chemistry of adenosine, P2Y and P2X receptors , 2016, Neuropharmacology.

[3]  G. Burnstock.  P2X ion channel receptors and inflammation , 2016, Purinergic Signalling.

[4]  P. Correia‐de‐Sá,et al.  Up‐regulation of P2X7 receptor–mediated inhibition of GABA uptake by nerve terminals of the human epileptic neocortex , 2016, Epilepsia.

[5]  N. Van Rooijen,et al.  Mechanism of microglia neuroprotection: Involvement of P2X7, TNFα, and valproic acid , 2016, Glia.

[6]  T. Möller,et al.  Central nervous system myeloid cells as drug targets: current status and translational challenges , 2015, Nature Reviews Drug Discovery.

[7]  I. Matsuoka,et al.  P2X7 receptor antagonist activity of the anti-allergic agent oxatomide. , 2015, European journal of pharmacology.

[8]  D. Su,et al.  NLRP3 inflammasome and its inhibitors: a review , 2015, Front. Pharmacol..

[9]  P. Bonaventure,et al.  A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. , 2015, European journal of pharmacology.

[10]  M. Braddock,et al.  Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study , 2015, Inflammatory bowel diseases.

[11]  Jan Hillert,et al.  A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. , 2015, Human molecular genetics.

[12]  M. Meyer-Luehmann,et al.  Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-β plaque formation in organotypic hippocampal slice cultures , 2015, Scientific Reports.

[13]  D. Henshall,et al.  P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus , 2015, Epilepsy & Behavior.

[14]  R. Ransohoff,et al.  Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. , 2015, Trends in pharmacological sciences.

[15]  N. Carruthers,et al.  Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists. , 2015, ACS medicinal chemistry letters.

[16]  G. Hutchins,et al.  Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X(7) receptor. , 2015, Bioorganic & medicinal chemistry letters.

[17]  G. Hutchins,et al.  Synthesis of [11C]GSK1482160 as a new PET agent for targeting P2X7 receptor , 2015 .

[18]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[19]  C. Müller.  Medicinal chemistry of P2X receptors: allosteric modulators. , 2015, Current medicinal chemistry.

[20]  B. Trapp,et al.  Pathological mechanisms in progressive multiple sclerosis , 2015, The Lancet Neurology.

[21]  Alina Ghinet,et al.  Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential. , 2015, Current medicinal chemistry.

[22]  E. Scemes,et al.  Blockade of P2X7 Receptors or Pannexin-1 Channels Similarly Attenuates Postischemic Damage , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  N. Pochet,et al.  Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice , 2015, Annals of neurology.

[24]  Jin-Tai Yu,et al.  Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus , 2014, Journal of Neuroinflammation.

[25]  P. Bonaventure,et al.  Pharmacology of a Novel Central Nervous System–Penetrant P2X7 Antagonist JNJ-42253432 , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[26]  F. Di Virgilio,et al.  Possible protective role of the 489C>T P2X7R polymorphism in Alzheimer's disease , 2014, Experimental Gerontology.

[27]  B. Sperlágh,et al.  P2X7 receptor: an emerging target in central nervous system diseases. , 2014, Trends in pharmacological sciences.

[28]  M. Tremblay,et al.  Never-resting microglia: physiological roles in the healthy brain and pathological implications , 2014, Front. Cell. Neurosci..

[29]  K. Biber,et al.  Neuronal CC chemokines: the distinct roles of CCL21 and CCL2 in neuropathic pain , 2014, Front. Cell. Neurosci..

[30]  S. Baldwin,et al.  Non-Synonymous Single Nucleotide Polymorphisms in the P2X Receptor Genes: Association with Diseases, Impact on Receptor Functions and Potential Use as Diagnosis Biomarkers , 2014, International journal of molecular sciences.

[31]  L. Stokes,et al.  The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease , 2014, Pharmacological Reviews.

[32]  A. Lammertsma,et al.  Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [¹¹C]A-740003 as a novel tracer of neuroinflammation. , 2014, Journal of labelled compounds & radiopharmaceuticals.

[33]  R. Cunha,et al.  The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis , 2014, Neuropharmacology.

[34]  K. Biber,et al.  P2X7‐dependent, but differentially regulated release of IL‐6, CCL2, and TNF‐α in cultured mouse microglia , 2014, Glia.

[35]  I. Jalilian,et al.  Probenecid Blocks Human P2X7 Receptor-Induced Dye Uptake via a Pannexin-1 Independent Mechanism , 2014, PloS one.

[36]  M. Tremblay,et al.  Surveillance, Phagocytosis, and Inflammation: How Never-Resting Microglia Influence Adult Hippocampal Neurogenesis , 2014, Neural plasticity.

[37]  P. L. Fernández,et al.  Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis , 2014, Journal of Neuroinflammation.

[38]  F. Gage,et al.  Mutant Huntingtin Promotes Autonomous Microglia Activation via Myeloid Lineage-determining Factors Fold Difference from the Mean , 2022 .

[39]  Wen Li,et al.  Lack of Association of P2RX7 Gene rs2230912 Polymorphism with Mood Disorders: A Meta-Analysis , 2014, PloS one.

[40]  S. Gygi,et al.  Identification of a Unique TGF-β Dependent Molecular and Functional Signature in Microglia , 2013, Nature Neuroscience.

[41]  A. Nicke,et al.  The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor , 2013, Neuropharmacology.

[42]  M. Miras-Portugal,et al.  Purinergic P2X7 Receptors Mediate Cell Death in Mouse Cerebellar Astrocytes in Culture , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[43]  D. Henshall,et al.  P2X receptors as targets for the treatment of status epilepticus , 2013, Front. Cell. Neurosci..

[44]  Toshiro K. Ohsumi,et al.  The Microglial Sensome Revealed by Direct RNA Sequencing , 2013, Nature Neuroscience.

[45]  P. Bonaventure,et al.  Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567 , 2013, British journal of pharmacology.

[46]  Ukpong B. Eyo,et al.  P2X7 receptor activation regulates microglial cell death during oxygen-glucose deprivation , 2013, Neuropharmacology.

[47]  F. Heppner,et al.  Microglia actions in Alzheimer’s disease , 2013, Acta Neuropathologica.

[48]  M. Marcoli,et al.  Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism. , 2013, Toxicology.

[49]  C. Mooney,et al.  Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A‐438079 , 2013, Epilepsia.

[50]  E. Vizi,et al.  Neurochemical Changes in the Mouse Hippocampus Underlying the Antidepressant Effect of Genetic Deletion of P2X7 Receptors , 2013, PloS one.

[51]  U. Hanisch.  Functional diversity of microglia – how heterogeneous are they to begin with? , 2013, Front. Cell. Neurosci..

[52]  S. Baldwin,et al.  Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms , 2013, Front. Pharmacol..

[53]  Jingfa Zhang,et al.  Silencing of the P2X(7) receptor enhances amyloid-β phagocytosis by microglia. , 2013, Biochemical and biophysical research communications.

[54]  Christian Gieger,et al.  The Molecular Genetic Architecture of Self-Employment , 2013, PloS one.

[55]  B. Sperlágh,et al.  The role of glutamate release mediated by extrasynaptic P2X7 receptors in animal models of neuropathic pain , 2013, Brain Research Bulletin.

[56]  R. North,et al.  P2X Receptors as Drug Targets , 2013, Molecular Pharmacology.

[57]  P. Bonaventure,et al.  Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists. , 2013, ACS medicinal chemistry letters.

[58]  K. Jones,et al.  The role of the innate immune system in psychiatric disorders , 2013, Molecular and Cellular Neuroscience.

[59]  J. Yerbury,et al.  P2X7 Receptor Activation Induces Reactive Oxygen Species Formation and Cell Death in Murine EOC13 Microglia , 2013, Mediators of inflammation.

[60]  F. Rosenbauer,et al.  Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways , 2013, Nature Neuroscience.

[61]  F. Kirchhoff,et al.  Microglia: New Roles for the Synaptic Stripper , 2013, Neuron.

[62]  F. Geissmann,et al.  Development and homeostasis of “resident” myeloid cells: The case of the microglia , 2013, Glia.

[63]  U. Heinemann,et al.  Extracellular ATP differentially affects epileptiform activity via purinergic P2X7 and adenosine A1 receptors in naive and chronic epileptic rats , 2012, Epilepsia.

[64]  E. Keystone,et al.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine , 2012, Annals of the rheumatic diseases.

[65]  M. Schaefer,et al.  Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors , 2012, British journal of pharmacology.

[66]  J. Lucas,et al.  In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases , 2012, Neurobiology of Aging.

[67]  Sam R. Miller,et al.  Effects of genetic variation in the P2RX7 gene on pharmacodynamics of a P2X(7) receptor antagonist: a prospective genotyping approach. , 2012, British journal of clinical pharmacology.

[68]  H. Okada,et al.  Anti-Prion Activity of Brilliant Blue G , 2012, PloS one.

[69]  C. Mebus,et al.  Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate , 2012, The Journal of Rheumatology.

[70]  D. Henshall,et al.  Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  A. Pérez-Samartín,et al.  P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia , 2012, Neurobiology of Disease.

[72]  B. Sperlágh,et al.  The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice , 2012, The international journal of neuropsychopharmacology.

[73]  A. Nimmerjahn,et al.  The Role of Microglia in the Healthy Brain , 2011, The Journal of Neuroscience.

[74]  P. Villoslada,et al.  Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. , 2011, Cell calcium.

[75]  A. Bhattacharya,et al.  The physiology, pharmacology and future of P2X7 as an analgesic drug target: hype or promise? , 2011, Current pharmaceutical biotechnology.

[76]  Lin-Hua Jiang,et al.  Pharmacological properties of the rhesus macaque monkey P2X7 receptor , 2011, British journal of pharmacology.

[77]  M. Bennett,et al.  Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test , 2011, Neuroscience.

[78]  A. Kalgutkar,et al.  Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. , 2011, Bioorganic & medicinal chemistry letters.

[79]  D. Schneider,et al.  The P2 Receptor Antagonist PPADS Supports Recovery from Experimental Stroke In Vivo , 2011, PloS one.

[80]  R. Fields,et al.  Nonsynaptic and nonvesicular ATP release from neurons and relevance to neuron-glia signaling. , 2011, Seminars in cell & developmental biology.

[81]  M. Landén,et al.  Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. , 2011, Journal of psychiatry & neuroscience : JPN.

[82]  M. Schaefer,et al.  Clemastine Potentiates the Human P2X7 Receptor by Sensitizing It to Lower ATP Concentrations* , 2011, The Journal of Biological Chemistry.

[83]  P. Hayter,et al.  Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat , 2011, British journal of pharmacology.

[84]  F. Ginhoux,et al.  Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.

[85]  G. Burnstock,et al.  Microglia: proliferation and activation driven by the P2X7 receptor. , 2010, The international journal of biochemistry & cell biology.

[86]  O. Sasso,et al.  Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor , 2010, Glia.

[87]  C. Parada,et al.  Peripheral mechanisms underlying the essential role of P2X7 receptors in the development of inflammatory hyperalgesia. , 2010, European journal of pharmacology.

[88]  S. Senger,et al.  Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor. , 2010, Bioorganic & medicinal chemistry letters.

[89]  S. Senger,et al.  Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptor. , 2010, Bioorganic & medicinal chemistry letters.

[90]  S. Fuller,et al.  Two haplotypes of the P2X7 receptor containing the Ala‐348 to Thr polymorphism exhibit a gain‐of‐function effect and enhanced interleukin‐1β secretion , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[91]  H. Saitoh,et al.  P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways , 2010, Neuroscience Research.

[92]  Betsy S. Pierce,et al.  Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist. , 2010, Bioorganic & medicinal chemistry letters.

[93]  S. Rapoport,et al.  Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients , 2010, Molecular Psychiatry.

[94]  S. McMahon,et al.  P2X7-Dependent Release of Interleukin-1β and Nociception in the Spinal Cord following Lipopolysaccharide , 2010, The Journal of Neuroscience.

[95]  D. Donnelly-roberts,et al.  The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1αβ knockout mice , 2009, Behavioural Brain Research.

[96]  E. Fonfria,et al.  Cloning and pharmacological characterization of the dog P2X7 receptor , 2009, British journal of pharmacology.

[97]  D. Donnelly-roberts,et al.  Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors , 2009, British journal of pharmacology.

[98]  T. Takano,et al.  Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury , 2009, Proceedings of the National Academy of Sciences.

[99]  J. Koo,et al.  Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. , 2009, Current opinion in investigational drugs.

[100]  J. Lucas,et al.  Altered P2X7‐receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[101]  W. C. Clay,et al.  Mechanism of action of species‐selective P2X7 receptor antagonists , 2009, British journal of pharmacology.

[102]  F. Di Virgilio,et al.  Activation of Microglia by Amyloid β Requires P2X7 Receptor Expression1 , 2009, The Journal of Immunology.

[103]  M. Decker,et al.  Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders , 2009, Behavioural Brain Research.

[104]  R. North,et al.  Signaling at purinergic P2X receptors. , 2009, Annual review of physiology.

[105]  D. Donnelly-roberts,et al.  [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors , 2009, Neuropharmacology.

[106]  A. Kataoka,et al.  Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT , 2009, Journal of neurochemistry.

[107]  J. Krause,et al.  Characterization of N-(Adamantan-1-ylmethyl)-5-[(3R-aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 Antagonist in Animal Models of Pain and Inflammation , 2008, Journal of Pharmacology and Experimental Therapeutics.

[108]  J. Ryu,et al.  Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer's disease , 2008, Neuroreport.

[109]  E. Audinat,et al.  Status Epilepticus Induces a Particular Microglial Activation State Characterized by Enhanced Purinergic Signaling , 2008, The Journal of Neuroscience.

[110]  A. Vezzani,et al.  Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1β production , 2008, Neurobiology of Disease.

[111]  I. Goshen,et al.  Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression , 2008, Molecular Psychiatry.

[112]  W. C. Clay,et al.  Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue , 2008, British journal of pharmacology.

[113]  A. Michel,et al.  Negative and positive allosteric modulators of the P2X7 receptor , 2008 .

[114]  R. Dantzer,et al.  In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1β in the murine brain , 2008, Brain, Behavior, and Immunity.

[115]  J. Koo,et al.  IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress , 2008, Proceedings of the National Academy of Sciences.

[116]  F. Rossi,et al.  Local self-renewal can sustain CNS microglia maintenance and function throughout adult life , 2007, Nature Neuroscience.

[117]  A. Mildner,et al.  Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions , 2007, Nature Neuroscience.

[118]  F. Di Virgilio,et al.  Liaisons dangereuses: P2X(7) and the inflammasome. , 2007, Trends in pharmacological sciences.

[119]  Amaia M. Arranz,et al.  P2X7 Receptor Blockade Prevents ATP Excitotoxicity in Oligodendrocytes and Ameliorates Experimental Autoimmune Encephalomyelitis , 2007, The Journal of Neuroscience.

[120]  D. Donnelly-roberts,et al.  P2X7-related modulation of pathological nociception in rats , 2007, Neuroscience.

[121]  I. Chessell,et al.  Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding , 2007, British journal of pharmacology.

[122]  D. Donnelly-roberts,et al.  A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[123]  Hyun B Choi,et al.  Upregulated Expression of Purinergic P2X7 Receptor in Alzheimer Disease and Amyloid-&bgr; Peptide-Treated Microglia and in Peptide-Injected Rat Hippocampus , 2006, Journal of neuropathology and experimental neurology.

[124]  A. Vezzani,et al.  Inactivation of Caspase‐1 in Rodent Brain: A Novel Anticonvulsive Strategy , 2006, Epilepsia.

[125]  D. Donnelly-roberts,et al.  Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. , 2006, Journal of medicinal chemistry.

[126]  E. Lynd-Balta,et al.  P2X7 receptor immunoreactive profile confined to resting and activated microglia in the epileptic brain , 2006, Brain Research.

[127]  C. Brosnan,et al.  Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[128]  C. Brosnan,et al.  Exacerbation of Experimental Autoimmune Encephalomyelitis in P2X7R−/− Mice: Evidence for Loss of Apoptotic Activity in Lymphocytes1 , 2006, The Journal of Immunology.

[129]  F. Helmchen,et al.  Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.

[130]  P. Anand,et al.  Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain , 2005, Pain.

[131]  C. Gabel,et al.  Absence of the P2X7 Receptor Alters Leukocyte Function and Attenuates an Inflammatory Response , 2002, The Journal of Immunology.

[132]  R. North,et al.  Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. , 2000, Molecular pharmacology.

[133]  T. van Biesen,et al.  Pharmacological characterization of recombinant human and rat P2X receptor subtypes. , 1999, European journal of pharmacology.

[134]  A. Vezzani,et al.  Interleukin-1β Immunoreactivity and Microglia Are Enhanced in the Rat Hippocampus by Focal Kainate Application: Functional Evidence for Enhancement of Electrographic Seizures , 1999, The Journal of Neuroscience.

[135]  E. Barnard,et al.  Cloning and functional characterisation of the mouse P2X7 receptor , 1998, FEBS letters.

[136]  E. Kawashima,et al.  The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7) , 1996, Science.

[137]  R. Scott,et al.  A rare P 2 X 7 variant Arg 307 Gln with absent pore formation function protects against neuroin fl ammation in multiple sclerosis , 2015 .

[138]  S. Najjar,et al.  Neuroinflammation and white matter pathology in schizophrenia: systematic review , 2015, Schizophrenia Research.

[139]  D. Bouvier,et al.  Synergistic actions of microglia and astrocytes in the progression of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[140]  M. Malcangio,et al.  The role of glia in the spinal cord in neuropathic and inflammatory pain. , 2015, Handbook of experimental pharmacology.

[141]  Paola Fabbrizio,et al.  Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis , 2014, Molecular Neurobiology.

[142]  F. Kapczinski,et al.  Role of P2X7 Receptor in an Animal Model of Mania Induced by D-Amphetamine , 2014, Molecular Neurobiology.

[143]  Manjinder Singh,et al.  Purinergic receptor P2X₇: a novel target for anti-inflammatory therapy. , 2014, Bioorganic & medicinal chemistry.

[144]  A. Pérez-Samartín,et al.  ATP Signaling in Brain: Release, Excitotoxicity and Potential Therapeutic Targets , 2014, Cellular and Molecular Neurobiology.

[145]  A. Bhattacharya,et al.  P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders. , 2014, Progress in medicinal chemistry.

[146]  J. Richardson,et al.  Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. , 2013, British journal of clinical pharmacology.

[147]  E. Bongarzone,et al.  P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. , 2008, Journal of neuroinflammation.

[148]  D. Walter,et al.  Negative and positive allosteric modulators of the P2X(7) receptor. , 2008, British journal of pharmacology.

[149]  R. Dantzer,et al.  In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1 beta in the murine brain. , 2008, Brain, behavior, and immunity.

[150]  Amaia M. Arranz,et al.  P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[151]  Kazuhide Inoue.  ATP receptors of microglia involved in pain. , 2006, Novartis Foundation symposium.